ITIL-168

N/A

Report date: 2023/03/16 20:00:26

Base Information

Drug NameITIL-168
Drug Alias NameITIL-168
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionLymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSkin MelanomaUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInstil Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInstil Bio Inc
Active IndicationsN/A
Inactive IndicationsSkin MelanomaUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 

Other Information

ATC CodeN/A
Related LinksN/A